The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+prostate cancer cells by downregulating wnt, NF-?B and AKT signaling

Basit Öğe Kaydı
dc.authoridSERTTAS, RIZA/0000-0002-7493-0388
dc.authoridERDOGAN, SUAT/0000-0002-6823-6293
dc.authorwosidSERTTAS, RIZA/AAG-7463-2020
dc.contributor.authorErdogan, Suat
dc.contributor.authorSerttas, Riza
dc.contributor.authorTurkekul, Kader
dc.contributor.authorDibirdik, Ilker
dc.date.accessioned2024-06-12T10:52:20Z
dc.date.available2024-06-12T10:52:20Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Tumor-initiating or cancer stem cells (CSCs) reduce the effectiveness of conventional therapy. Thus, it is crucial to eliminate CSCs while killing bulky cancer cells using a combination of conventional chemotherapy and anti-CSC drugs. Salinomycin is a selective inhibitor against CSCs and shows promise in combination applications. The aim of the study was to examine the efficacy of co-administered cabazitaxel and salinomycin on the survival of prostate cancer cells and CSCs. Methods and Results CD44 + stem cells were isolated from human PC3 prostate cancer cells by using magnetic activated cell sorting. The cells were concomitantly exposed to salinomycin and cabazitaxel, and the cell survival was determined by MTT test. Apoptosis was assessed by image-based cytometer, and cell migration was evaluated by wound healing assay. The expression of target mRNA and protein were assessed by RT-qPCR and Western blot, respectively. Combination index (CI) analysis showed that simultaneous administration of salinomycin and cabazitaxel was able to exert strong synergistic effect on CD44 + subpopulation (CI = 0.33), but no synergism was observed in PC3 cells. The combination of the two agents significantly increased Bax, cytochrome c, caspase-3 and - 8 mRNA expression in CD44 + CSCs, causing apoptosis. The applied therapy strategy strongly inhibited the phosphorylation of Akt, protein expression of Akt1, NF-kappa B and Wnt. Conclusions In conclusion, our data suggest that combining salinomycin with cabazitaxel shows promise as a prostate cancer treatment approach that can target CSCs.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Trakya University [2018-312]en_US
dc.description.sponsorshipThis study was funded by Scientific Research Projects Coordination Unit of Trakya University (Project number: 2018-312).en_US
dc.identifier.doi10.1007/s11033-022-07343-y
dc.identifier.endpage4884en_US
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue6en_US
dc.identifier.pmid35705771en_US
dc.identifier.scopus2-s2.0-85132197882en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage4873en_US
dc.identifier.urihttps://doi.org/10.1007/s11033-022-07343-y
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18680
dc.identifier.volume49en_US
dc.identifier.wosWOS:000811415900004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofMolecular Biology Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectApoptosisen_US
dc.subjectCabazitaxelen_US
dc.subjectCancer Stem Cellen_US
dc.subjectCD44en_US
dc.subjectProstate Canceren_US
dc.subjectSalinomycinen_US
dc.subjectStem-Cellsen_US
dc.subjectDocetaxelen_US
dc.subjectApoptosisen_US
dc.subjectMigrationen_US
dc.subjectNanoparticlesen_US
dc.subjectSurvivalen_US
dc.subjectDeliveryen_US
dc.subjectTargeten_US
dc.titleThe synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+prostate cancer cells by downregulating wnt, NF-?B and AKT signalingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu